Allogene Therapeutics (ALLO) Net Margin (2021 - 2024)

Allogene Therapeutics has disclosed Net Margin across 4 years of filings, most recently posting 291231.82% for Q1 2024.

• Net Margin for Q1 2024 came in at 291231.82%, up 3221152.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 1151031.82% (down 82531603.0% YoY), and the FY2024 annual result was 1170863.64%, down 82637416.0% from the prior year.
• Net Margin came in at 291231.82% for Q1 2024 at Allogene Therapeutics, up from 375447.62% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 2.5% in Q4 2021 to a low of 375447.62% in Q4 2023.
• The 4-year median for Net Margin is 258140.91% (2023), against an average of 223087.67%.
• Across the five-year window, Net Margin tumbled 36014866 bps in 2022 and soared 4374428 bps in 2023, its largest moves.
• Allogene Therapeutics' Net Margin stood at 2.5% in 2021, then plunged by 14392819 bps to 360146.15% in 2022, then retreated by 4 bps to 375447.62% in 2023, then gained by 22 bps to 291231.82% in 2024.
• The last three Net Margin figures came in at 291231.82% (Q1 2024), 375447.62% (Q4 2023), and 258140.91% (Q3 2023), per Business Quant data.